Ratiopharm gives more pep to levfin pipeline after AB InBev boost
Early stage discussions over a potential financing of up to Eu1bn for the acquisition of Ratiopharm, the German generic drugs firm, gave leveraged finance bankers more to cheer this week, even as the largest European buy-out of the year was completed.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
